GlassScriptPhysician profile
Mason David Mckee
NPI 1942949128
$8,437.93
in general payments reported to CMS, 2019-2025
30 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $396 · 2023: $3,587 · 2024: $3,203 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,016 · Education: $25.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,016.36 |
| Education | $25.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,881.36 | 2022-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,767.90 | 2022-2025 | |
| Amgen INC. | $1,576.19 | 2023-2025 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $554.38 | 2023-2025 | |
| Lilly USA, LLC | $404.74 | 2022-2024 | Taltz |
| Organon LLC | $351.40 | 2023-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $247.50 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.55 | 2022-2025 | Ofev, Cyltezo |
| Genzyme Corporation | $194.72 | 2023-2025 | |
| Horizon Therapeutics Plc | $181.50 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $166.90 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $143.08 | 2023-2025 | Acthar |
| Kyowa Kirin, INC. | $102.47 | 2023-2025 | Crysvita |
| Fresenius Kabi USA, LLC | $83.94 | 2024-2025 | Tyenne |
| Octapharma USA, INC. | $68.89 | 2024 | Octagam Immune Globulin (Human) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $64.12 | 2023-2024 | Vegzelma, Yuflyma |
| Sandoz INC. | $60.05 | 2024 | Hyrimoz |
| Almatica Pharma LLC | $45.93 | 2024 | Teriparatide |
| Aurinia Pharma U.S., INC. | $44.56 | 2022-2025 | Lupkynis |
| Genentech USA, INC. | $41.34 | 2023-2024 | Actemra, Rituxan |
| E.R. Squibb & Sons, L.L.C. | $35.40 | 2024-2025 | Orencia |
| Ferring Pharmaceuticals INC. | $33.55 | 2023-2024 | Euflexxa |
| Kiniksa Pharmaceuticals International, Plc | $27.62 | 2024 | Arcalyst |
| Alvogen INC | $25.08 | 2024 | Teriparatide |
| Stryker Corporation | $24.31 | 2025 | Inthrill Thrombectomy Catheter |
| Actelion Pharmaceuticals US, INC. | $18.40 | 2022 | |
| Janssen Biotech, INC. | $16.77 | 2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $15.72 | 2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $14.34 | 2023 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $14.22 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.